Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., . . . Thakurta, A. G. (2015). Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J.
Citação norma ChicagoBjorklund, C C., et al. "Rate of CRL4(CRBN) Substrate Ikaros and Aiolos Degradation Underlies Differential Activity of Lenalidomide and Pomalidomide in Multiple Myeloma Cells By Regulation of C-Myc and IRF4." Blood Cancer J 2015.
Citação norma MLABjorklund, C C., et al. "Rate of CRL4(CRBN) Substrate Ikaros and Aiolos Degradation Underlies Differential Activity of Lenalidomide and Pomalidomide in Multiple Myeloma Cells By Regulation of C-Myc and IRF4." Blood Cancer J 2015.